A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study

Trial Profile

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Lampalizumab (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions; Registrational
  • Acronyms Omaspect
  • Sponsors Roche
  • Most Recent Events

    • 13 Oct 2017 The study has been suspended in Portugal.
    • 04 Oct 2017 The study has been suspended in Austria.
    • 27 Sep 2017 This trial has been suspended in Denmark.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top